Preoperative serum hCGβ as a prognostic marker in primary fallopian tube carcinoma

Tumor Biology

Volumn 27, Issue 1, 2006, Pages 43-49

  Riska, A ^a   Alfthan, H ^a   Finne, P ^a,b   Jalkanen, J ^a   Sorvari, T ^a   Stenman, U H ^a   Leminen, A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Human chorionic gonadotropin; Primary fallopian tube carcinoma; Tumour associated trypsin inhibitor

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; APROTININ;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; SURVIVAL RATE; UTERINE TUBE CARCINOMA; BLOOD; CANCER STAGING; FLUORESCENT ANTIBODY TECHNIQUE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; UTERINE TUBE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRYPSIN INHIBITOR, KAZAL PANCREATIC;

EID: 29244466426     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090155     Document Type: Article

References (35)

1. Nordin AJ: Primary carcinoma of fallopian tube: a 20-year literature review. Obstet Gynecol Surv 1994;49:349-361.
2. Riska A, Leminen A, Pukkala E: Sociodemographic determinants of incidence of primary fallopian tube carcinoma. Int J Cancer 2003;104:643-645.
3. Rosen AC, Ausch CH, Hafner E, Klein M, Lahousen M, Graf AH, Reiner A, the Austrian Cooperative Study Group for Fallopian Tube Carcinoma: A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Eur J Cancer 1998;34:1725-1729.
4. Jereczek B, Jassem J, Kobierska A: Primary cancer of the fallopian tube. Report of 26 patients. Acta Obstet Gynecol Scand 1996;75:281-286.
5. Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G: Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 2001;81:150-159.
6. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM: Carcinoma of the fallopian tube. Clinicopathological study of 151 patients treated at the Norwegian Radium Hospital. Cancer 2000;89:2076-2084.
7. Peters WA, Andersen WA, Hopkins MP, Kumar NB, Morley GW: Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 1988;71:757-762.
8. Hefler LA, Rosen AC, Graf AH, Lahousen M, Klein M, Leodolter S, Reinthaller A, Kainz C, Tempfer CB: The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma. A multicenter study. Cancer 2000;89:1555-1560.
9. Rosen AC, Klein M, Hafner E, Lahousen M, Graf AH, Reiner A, the Austrian Cooperative Study Group for Fallopian Tube Carcinoma: management and prognosis of primary fallopian tube carcinoma. Gynecol Obstet Invest 1999;47:45-51.
10. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills BG: CA 125: the past and the future. Int J Biol Markers 1998;13:179-187.
11. Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT: Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med 1973;78:39-45.
12. Marcillac I, Troalen FF, Bidart JM, Ghillani P, Ribrag V, Escudier B, Malassagne B, Droz JP, Lhomme C, Rougier P, et al: Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 1992;52:3901-3907.
13. Ind T, Iles R, Shepherd J, Chard T: Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br J Obstet Gynaecol 1997;104:1024-1029.
14. Vartiainen J, Lehtovirta P, Finne P, Stenman UH, Alfthan H: Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int J Cancer 2001;95:313-316.
15. Carpelan-Holmström M, Haglund C, Lundin J, Alfthan H, Stenman UH, Roberts PJ: Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 1996;74:925-929.
16. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B: Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 2001;165:959-962.
17. Alfthan H, Haglund C, Roberts P, Stenman UH: Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 2000;52:4628-4633.
18. Carter PG, Iles RK, Neven P, Ind TE, Shepherd JH, Chard T: Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance. Br J Cancer 1995;71:350-353.
19. Carter PG, Iles RK, Neven P, Ind TE, Shepherd JH, Chard T: The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix. Gynecol Oncol 1994;55:271-276.
20. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O: Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 1994;70:1188-1190.
21. Kelloniemi E, Rintala E, Finne P, Stenman UH, Group F: Tumor-associated trypsin inhibitor (TATI) as a prognostic marker during follow-up of bladder cancer. Urology 2003;62:249-253.
22. Alfthan H, Schroder J, Fraser R, Koskimies A, Halila H, Stenman UH: Choriogonadotropin and its beta subunit separated by hydrophobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays. Clin Chem 1988;34:1758-1762.
23. Alfthan H, Haglund C, Dabek J, Stenman UH: Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Endocrinology 1992;131:1832-1840.
24. Cox DR: Regression models and life tables. J R Stat Soc B 1972;34:187-220.
25. Louhimo J, Carpelan-Holmstrom M, Stenman UH, Jarvinen HJ, Haglund C: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002;101:545-548.
26. Lundin M, Nordling S, Lundin J, Alfthan H, Stenman UH, Haglund C: Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer 2001;95:18-20.
27. Rosen AC, Klein M, Rosen HR, Graf AH, Lahousen M, Reiner A, Vavra N, Auerbech L: Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma. Arch Gynecol Obstet 1994;255:65-68.
28. Venesmaa P, Stenman UH, Forss M, Leminen A, Lehtovirta P, Vartiainen J, Paavonen J: Preoperative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. Br J Obstet Gynaecol 1998;105:508-511.
29. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, Wahlström T, Stenman UH: Expression of trypsinogen-1. trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 2004,10:4761-4768.
30. Eddy GL, Copeland LJ, Gershenson DM, Atkinson EN, Wharton JT, Rutledge FN: Fallopian tube carcinoma. Obstet Gynecol 1984;64:546-552.
31. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE: Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999;72:367-379.
32. Zweemer RP, van Diest PJ, Verheijen RHM, Ryan A, Gille JJP, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P: Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
33. Butler SA, Ikram MS, Mathieu S, Iles RK: The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer 2000;82:1553-1556.
34. Devi GR, Oldenkamp JR, London CA, Iversen PL: Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002;53:200-210.
35. He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, Valkova-Valchanova M, Arunakumari A, Treml JF, Goldstein J, Wallace PK, Keler T, Endres MJ: A novel human cancer vaccine elicits cellular response to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res 2004;10:1920-1927.